World Library  
Flag as Inappropriate
Email this Article


Systematic (IUPAC) name
Clinical data
Pronunciation ,
Trade names Lopressor, Metolar XR
Licence data US FDA:
  • AU: C
  • US: C (Risk not ruled out)
Legal status
  • (Prescription only)
Routes of
Oral, IV
Pharmacokinetic data
Bioavailability 50%[1]
Protein binding 12%
Metabolism Liver via CYP2D6, CYP3A4
Biological half-life 3-7 hours
Excretion Kidney
CAS Registry Number  Y
ATC code C07
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C15H25NO3
Molecular mass 267.364 g/mol
Physical data
Melting point 120 °C (248 °F)

Metoprolol, marketed under the tradename Lopressor among others, is a selective health system.[8] It is available as a generic drug.[2] In 2013, metoprolol was the 19th most prescribed medication in the United States.[9]


  • Medical uses 1
  • Adverse effects 2
    • Precautions 2.1
    • Overdosage 2.2
  • Pregnancy and lactation 3
  • Physical properties 4
  • Metabolism 5
  • Pharmacology 6
  • Brand names 7
  • References 8
  • External links 9

Medical uses

Metoprolol is used for a number of conditions, including hypertension, angina, acute myocardial infarction, supraventricular tachycardia, ventricular tachycardia, congestive heart failure, and prevention of migraine headaches.[10]

Due to its selectivity in blocking the beta1 receptors in the heart, metoprolol is also prescribed for off-label use in performance anxiety, social anxiety disorder, and other anxiety disorders.

Adverse effects

Side effects, especially with higher doses, include dizziness, drowsiness, fatigue, diarrhea, unusual dreams, ataxia, trouble sleeping, depression, and vision problems. It may also reduce blood flow to the hands and feet, causing them to feel numb and cold; smoking may worsen this effect.[16] Due to the high penetration across the blood-brain barrier, lipophilic beta blockers such as propranolol and metoprolol are more likely than other less lipophilic beta blockers to cause sleep disturbances such as insomnia and vivid dreams and nightmares.[17]

Serious side effects that are advised to be reported immediately include symptoms of bradycardia (resting heart rate slower than 60 beats per minute), persistent symptoms of dizziness, fainting and unusual fatigue, bluish discoloration of the fingers and toes, numbness/tingling/swelling of the hands or feet, sexual dysfunction, erectile dysfunction (impotence), hair loss, mental/mood changes, depression, trouble breathing, cough, dyslipidemia, and increased thirst. Other highly unlikely symptoms include easy bruising or bleeding, persistent sore throat or fever, yellowing skin or eyes, stomach pain, dark urine, and persistent nausea. Symptoms of an allergic reaction include rash, itching, swelling, and severe dizziness. Taking it with alcohol might cause mild body rashes, so is not recommended.[16]


Metoprolol may worsen the symptoms of heart failure in some patients, who may experience chest pain or discomfort, dilated neck veins, extreme fatigue, irregular breathing, an irregular heartbeat, shortness of breath, swelling of the face, fingers, feet, or lower legs, weight gain, or wheezing.[18]

This medicine may cause changes in blood sugar levels or cover up signs of low blood sugar, such as a rapid pulse rate.[18] It also may cause some people to become less alert than they are normally, making it dangerous for them to drive or use machines.[18]


Excessive doses of metoprolol can cause severe hypotension, bradycardia, metabolic acidosis, seizures, and cardiorespiratory arrest. Blood or plasma concentrations may be measured to confirm a diagnosis of overdose or poisoning in hospitalized patients or to assist in a medicolegal death investigation. Plasma levels are usually less than 200 μg/l during therapeutic administration, but can range from 1–20 mg/l in overdose victims.[19][20][21]

Pregnancy and lactation

It is pregnancy category C in the United States and category C in Australia, meaning evidence of harm is possible.[2][5]

Physical properties

Metoprolol has a very low melting point, the tartrate's is around 120 °C (248 °F), and the succinate's around 136 °C (277 °F). Because of this, metoprolol is always manufactured in a salt-based solution, as drugs with low melting points are difficult to work with in a manufacturing environment. The free base exists as a waxy white solid, and the tartrate salt is finer crystalline material.[22]

The active substance metoprolol is employed either as metoprolol succinate or as metoprolol tartrate (where 100 mg metoprolol tartrate corresponds to 95 mg metoprolol succinate). The tartrate is an immediate-release and the succinate is an extended-release formulation.[23]


Metoprolol undergoes a-hydroxylation and O-demethylation as a substrate of the cytochrome liver enzymes CYP2D6[24][25] and a small percentage by CYP3A4.


  • Selective
  • Moderately lipophilic
  • Without intrinsic sympathomimetic activity
  • With weak membrane stabilizing activity
  • Short half-life, therefore must be taken at least twice daily or as a slow-release preparation
  • Decreases heart rate, contractility, and cardiac output, therefore decreasing blood pressure
  • Metabolized in the liver to inactive metabolite

Brand names

Toprol XL 50 mg

It is marketed under the brand name Lopressor by Novartis, and Toprol-XL (in the USA); Selokeen (in the Netherlands); as Minax by Alphapharm and Metrol by Arrow Pharmaceuticals (in Australia), as Betaloc by AstraZeneca, as Bloxan by Krka (company) (in Slovenia), as Neobloc by Unipharm (in Israel), Presolol by Hemofarm (in Serbia), and Corvitol by Berlin-Chemie AG (in Germany). In India, this drug is available under the brand names Met-XL, Metolar, Starpress, and Restopress. A number of generic products are available, as well.


  1. ^ "Metolar 25/50 (metoprolol tartrate) tablet" (PDF). FDA. Retrieved 5 May 2015. 
  2. ^ a b c d e f g h i "Metoprolol". The American Society of Health-System Pharmacists. Retrieved Apr 21, 2014. 
  3. ^ Pillay (2012). Modern Medical Toxicology. Jaypee Brothers Publishers. p. 303.  
  4. ^ Marx, John A. Marx (2014). "Cardiovascular Drugs". Rosen's emergency medicine : concepts and clinical practice (8th ed.). Philadelphia, PA: Elsevier/Saunders. pp. Chapter 152.  
  5. ^ a b "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Retrieved 22 April 2014. 
  6. ^ Medical Toxicology. Lippincott Williams & Wilkins. 2004. p. 684.  
  7. ^ Carlsson, edited by Bo (1997). Technological systems and industrial dynamics. Dordrecht: Kluwer Academic. p. 106.  
  8. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  9. ^ "Top 100 Drugs for 2013 by Units Sold". 2014-02. Retrieved 22 March 2015. 
  10. ^ "Metoprolol". The American Society of Health-System Pharmacists. Retrieved 3 April 2011. 
  11. ^ MERIT-HF Study Group (1999). "Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)". Lancet 353 (9169): 2001–2007.  
  12. ^ Biffi, M.; Boriani, G.; Sabbatani, P.; Bronzetti, G.; Frabetti, L.; Zannoli, R.; Branzi, A.; Magnani, B. (Mar 1997). "Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.". Heart 77 (3): 268–72.  
  13. ^ Zhang Q, Jin H, Wang L, Chen J, Tang C, Du J (2008). "Randomized comparison of metoprolol versus conventional treatment in preventing recurrence of vasovagal syncope in children and adolescents". Medical Science Monitor 14 (4): CR199–CR203.  
  14. ^ Geffner DL, Hershman JM (July 1992). "β-Adrenergic blockade for the treatment of hyperthyroidism". The American Journal of Medicine 93 (1): 61–8.  
  15. ^ Kühlkamp, V; Schirdewan, A; Stangl, K; Homberg, M; Ploch, M; Beck, OA (2000). "Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation". J Am Coll Cardiol 36 (1): 139–146.  
  16. ^ a b "Metoprolol". 
  17. ^ Cruickshank JM (2010). "Beta-blockers and heart failure". Indian Heart Journal 62 (2): 101–110.  
  18. ^ a b c "Metoprolol (Oral Route) Precautions". Drug Information. Mayo Clinic. 
  19. ^ Page C, Hacket LP, Isbister GK (2009). "The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report". Journal of Medical Toxicology 5 (3): 139–143.  
  20. ^ Albers S, Elshoff JP, Völker C, Richter A, Läer S (2005). "HPLC quantification of metoprolol with solid-phase extraction for the drug monitoring of pediatric patients". Biomedical Chromatography 19 (3): 202–207.  
  21. ^ Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 1023–1025. 
  22. ^ .(Metox-Wockhardt)
  23. ^ Cupp M (2009). "Alternatives for Metoprolol Succinate" (pdf). Pharmacist's Letter / Prescriber's Letter 25 (250302). Retrieved 2012-07-06. 
  24. ^ Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ (2005). "Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol". Clinical Pharmacokinetics 44 (10): 1067–1081.  
  25. ^ Blake, CM.; Kharasch, ED.; Schwab, M.; Nagele, P. (Sep 2013). "A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.". Clin Pharmacol Ther 94 (3): 394–9.  

External links

  • AstraZeneca's page for Toprol-XL
  • Novartis's page for Lopressor (PDF)
  • U.S. National Library of Medicine: Drug Information Portal - Metoprolol
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.